New agents in the management of non-small-cell lung cancer

A. Chiappori, R. F. Devore, D. H. Johnson

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Non-small-cell carcinoma of the lung has long been considered a chemotherapeutically resistant neoplasm. Newer agents and combinations are being tested. Methods: The authors have reviewed data on recent and active phase I and phase II trials of several new agents and combinations. Results: New drugs that affect both response rates and survival include vinorelbine, paclitaxel, docetaxel, gemcitabine, topotecan, and irinotecan. Conclusions: The advent of several relatively well-tolerated agents that alone have beneficial effects in advanced non-small-cell lung cancer provides reasonable hope that more effective drug combinations will soon be available for this disease.

Original languageEnglish (US)
Pages (from-to)317-325
Number of pages9
JournalCancer Control
Volume4
Issue number4
StatePublished - 1997

Fingerprint

irinotecan
docetaxel
gemcitabine
Non-Small Cell Lung Carcinoma
Topotecan
Drug Combinations
Paclitaxel
Pharmaceutical Preparations
Neoplasms
vinorelbine

ASJC Scopus subject areas

  • Oncology

Cite this

New agents in the management of non-small-cell lung cancer. / Chiappori, A.; Devore, R. F.; Johnson, D. H.

In: Cancer Control, Vol. 4, No. 4, 1997, p. 317-325.

Research output: Contribution to journalArticle

Chiappori, A, Devore, RF & Johnson, DH 1997, 'New agents in the management of non-small-cell lung cancer', Cancer Control, vol. 4, no. 4, pp. 317-325.
Chiappori, A. ; Devore, R. F. ; Johnson, D. H. / New agents in the management of non-small-cell lung cancer. In: Cancer Control. 1997 ; Vol. 4, No. 4. pp. 317-325.
@article{2eacffb49d6c4f98a17f3f9cfdb2c823,
title = "New agents in the management of non-small-cell lung cancer",
abstract = "Background: Non-small-cell carcinoma of the lung has long been considered a chemotherapeutically resistant neoplasm. Newer agents and combinations are being tested. Methods: The authors have reviewed data on recent and active phase I and phase II trials of several new agents and combinations. Results: New drugs that affect both response rates and survival include vinorelbine, paclitaxel, docetaxel, gemcitabine, topotecan, and irinotecan. Conclusions: The advent of several relatively well-tolerated agents that alone have beneficial effects in advanced non-small-cell lung cancer provides reasonable hope that more effective drug combinations will soon be available for this disease.",
author = "A. Chiappori and Devore, {R. F.} and Johnson, {D. H.}",
year = "1997",
language = "English (US)",
volume = "4",
pages = "317--325",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "4",

}

TY - JOUR

T1 - New agents in the management of non-small-cell lung cancer

AU - Chiappori, A.

AU - Devore, R. F.

AU - Johnson, D. H.

PY - 1997

Y1 - 1997

N2 - Background: Non-small-cell carcinoma of the lung has long been considered a chemotherapeutically resistant neoplasm. Newer agents and combinations are being tested. Methods: The authors have reviewed data on recent and active phase I and phase II trials of several new agents and combinations. Results: New drugs that affect both response rates and survival include vinorelbine, paclitaxel, docetaxel, gemcitabine, topotecan, and irinotecan. Conclusions: The advent of several relatively well-tolerated agents that alone have beneficial effects in advanced non-small-cell lung cancer provides reasonable hope that more effective drug combinations will soon be available for this disease.

AB - Background: Non-small-cell carcinoma of the lung has long been considered a chemotherapeutically resistant neoplasm. Newer agents and combinations are being tested. Methods: The authors have reviewed data on recent and active phase I and phase II trials of several new agents and combinations. Results: New drugs that affect both response rates and survival include vinorelbine, paclitaxel, docetaxel, gemcitabine, topotecan, and irinotecan. Conclusions: The advent of several relatively well-tolerated agents that alone have beneficial effects in advanced non-small-cell lung cancer provides reasonable hope that more effective drug combinations will soon be available for this disease.

UR - http://www.scopus.com/inward/record.url?scp=0030776238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030776238&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030776238

VL - 4

SP - 317

EP - 325

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 4

ER -